How has been the historical performance of ERIS Lifescience?

Answer:The historical performance of ERIS Lifescience shows significant growth in net sales and operating profit over the years, with net sales reaching 2,893.64 Cr in March 2025, up from 1,074.06 Cr in March 2020. The operating profit (PBDIT) also increased to 1,035.56 Cr in March 2025 from 376.60 Cr in March 2019. However, profit after tax saw fluctuations, peaking at 406.11 Cr in March 2022 before declining to 351.84 Cr in March 2025. The company's total assets grew from 1,381.39 Cr in March 2020 to 6,744.13 Cr in March 2025, while total liabilities increased from 1,381.39 Cr to 6,744.13 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,065.00 Cr in March 2025 compared to 271.00 Cr in March 2020. Breakdown: ERIS Lifescience has demonstrated a robust upward trend in its financial performance, particularly in net sales, which surged from 1,074.06 Cr in March 2020 to 2,893.64 Cr in March 2025. This growth in revenue is accompanied by a notable increase in operating profit, which rose from 376.60 Cr to 1,035.56 Cr over the same period. Despite this positive trend, profit after tax experienced some volatility, peaking at 406.11 Cr in March 2022 before settling at 351.84 Cr in March 2025. The company's total assets expanded significantly, reflecting its growth strategy, climbing from 1,381.39 Cr to 6,744.13 Cr. Total liabilities mirrored this growth, also increasing to 6,744.13 Cr. Cash flow from operating activities saw a remarkable improvement, indicating enhanced operational efficiency, with figures rising from 271.00 Cr in March 2020 to 1,065.00 Cr in March 2025.